CRSPR at SupportWeekly Chart of CRISPR.
At a support( demand zone).
As soon as it takes of 138 stock will come under bullish territory.
Long CRSPR.
Remember Weekly Charts are used for Investmet Duration greater than 3 months.
−15.298 BRL
−746.77 M BRL
1.80 B BRL
81.67 M
About CRISPR Therapeutics AG
Sector
Industry
CEO
Samarth Kulkarni
Website
Headquarters
Zug
Founded
2013
ISIN
BRC2RSBDR005
FIGI
BBG014XJ2N63
CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.
Displays a symbol's price movements over previous years to identify recurring trends.